Filing Flows › Protalix BioTherapeutics (PLX) › Q2 2025
Protalix BioTherapeutics (PLX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Protalix BioTherapeutics (PLX) reported revenue of $15.7M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +55% from the quarter before. Operating margin was 7.5%, net earnings $164K (1.0% of revenue).
Protalix BioTherapeutics, Q2 2025: revenue $15.7M (+16% year over year), operating margin 7.5%, net earnings $164K, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.7M | +55% | +16% |
| Operating profit | $1.2M | — | — |
| Net earnings | $164K | — | — |
| Operating cash flow | −$5.2M | — | — |
What changed
Revenue was $15.7M in Q2 2025, up 16% year over year and up 55% from the previous quarter. GOODS was the largest line at 99% of revenue. GOODS added $2.1M year over year (up 16%), 98% of the total change.
Operating profit was $1.2M, a 7.5% margin (up 25.5 points year over year). Total costs fell 9% while revenue rose 16%. The fastest-growing cost line was Research & development (+102%). Net earnings were $164K. The effective tax rate was 75.2%.
Operating cash flow was −$5.2M. Non-cash charges added back $360K of depreciation and $427K of share-based compensation. Working capital and other items used $6.2M. Capital expenditures of $431K exceeded it, leaving free cash flow of −$5.7M.
Questions
What was Protalix BioTherapeutics' revenue in the second quarter 2025?
Protalix BioTherapeutics (PLX) reported revenue of $15.7M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +55% from the quarter before.
Was Protalix BioTherapeutics profitable in the second quarter 2025?
Operating profit was $1.2M (7.5% of revenue) and net earnings $164K.